Want to see JP:2927 full AI Analyst Report?
Top Page
AFC-HD AMS Life Science Co., Ltd.
(2927)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥931.00
▲(7.75% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by attractive valuation (low P/E and high dividend yield) and moderately constructive technicals. Offsetting these positives, financial quality is constrained by weak free cash flow (negative in recent years) and elevated leverage, which raise risk if growth does not translate into durable cash generation.
Positive Factors
Accelerating revenue growth
Consistent acceleration in top-line growth across recent years implies durable demand and successful product or channel execution in health and life-science segments. Over the medium term this supports scale advantages, potential margin expansion, and funding optionality for reinvestment or debt reduction if cash conversion improves.
Negative Factors
Persistent negative free cash flow
Multi-year negative free cash flow signals that accounting profits are not translating into shareholder cash, likely due to investment intensity or working capital strain. Over 2–6 months this constrains capacity to repay debt, sustain dividends, or finance growth internally, increasing reliance on external financing or equity issuance.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating revenue growth
Consistent acceleration in top-line growth across recent years implies durable demand and successful product or channel execution in health and life-science segments. Over the medium term this supports scale advantages, potential margin expansion, and funding optionality for reinvestment or debt reduction if cash conversion improves.
Read all positive factors
AFC-HD AMS Life Science Co., Ltd. (2927) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥12.17B
Dividend Yield4.19%
Average Volume (3M)18.87K
Price to Earnings (P/E)10.3
Beta (1Y)0.43
Revenue Growth1.89%
EPS Growth-32.59%
CountryJP
Employees1,008
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)96.15
Shares Outstanding14,559,699
10 Day Avg. Volume18,160
30 Day Avg. Volume18,870
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)0.80
Price to Sales (P/S)0.37
P/FCF Ratio-6.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AFC-HD AMS Life Science Co., Ltd. Business Overview & Revenue Model
Company Description
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and cosmetics. The company operates through five segments: Healthcare, Pharmaceutical, Department Store, Food and Beverage, and Other Business. The He...
How the Company Makes Money
The company primarily makes money by selling health-related products and related services, with revenues generally coming from (1) manufacturing and sales of supplements/health foods and (2) life-science-related manufacturing/services connected to...
AFC-HD AMS Life Science Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
58
Neutral
Cash Flow
41
Neutral
| Breakdown | TTM | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.89B | 32.66B | 30.19B | 25.58B | 23.00B | 22.37B |
| Gross Profit | 11.21B | 10.97B | 10.49B | 9.32B | 8.58B | 6.87B |
| EBITDA | 3.64B | 3.80B | 3.10B | 2.59B | 2.30B | 2.86B |
| Net Income | 1.37B | 1.45B | 1.25B | 1.10B | 735.35M | 1.50B |
Balance Sheet | ||||||
| Total Assets | 50.25B | 48.73B | 47.03B | 41.07B | 37.35B | 35.75B |
| Cash, Cash Equivalents and Short-Term Investments | 11.09B | 11.30B | 12.17B | 11.18B | 10.38B | 9.22B |
| Total Debt | 23.76B | 24.14B | 23.40B | 19.59B | 17.24B | 14.77B |
| Total Liabilities | 34.03B | 33.53B | 33.07B | 27.91B | 24.90B | 23.09B |
| Stockholders Equity | 16.03B | 15.08B | 13.93B | 13.11B | 12.44B | 11.92B |
Cash Flow | ||||||
| Free Cash Flow | -1.75B | -1.75B | -1.87B | -1.07B | 534.45M | 2.09B |
| Operating Cash Flow | 1.79B | 1.79B | 1.54B | 865.28M | 1.49B | 2.58B |
| Investing Cash Flow | -3.33B | -3.33B | -2.76B | -1.95B | -1.08B | -274.97M |
| Financing Cash Flow | 666.75M | 666.75M | 2.23B | 1.88B | 1.16B | 2.19B |
AFC-HD AMS Life Science Co., Ltd. Technical Analysis
Positive
864.00
Price Trends
847.46
Positive
858.61
Positive
860.92
Positive
Market Momentum
3.85
Positive
60.04
Neutral
73.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2927, the sentiment is Positive. The current price of 864 is above the 20-day moving average (MA) of 861.65, above the 50-day MA of 847.46, and above the 200-day MA of 860.92, indicating a bullish trend. The MACD of 3.85 indicates Positive momentum. The RSI at 60.04 is Neutral, neither overbought nor oversold. The STOCH value of 73.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2927.
AFC-HD AMS Life Science Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥553.74B | 18.87 | ― | 2.93% | 1.68% | -11.62% | |
69 Neutral | ¥46.54B | 15.72 | ― | 1.98% | 2.00% | 97.05% | |
67 Neutral | ¥73.20B | 13.48 | ― | 3.43% | 0.75% | -23.26% | |
66 Neutral | ¥12.17B | 10.29 | ― | 3.94% | 1.89% | -32.59% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥33.84B | 10.32 | ― | 4.28% | 2.06% | -23.96% | |
54 Neutral | ¥13.72B | 100.78 | ― | ― | -1.94% | -69.93% |
* Consumer Defensive Sector Average
JP:2927
AFC-HD AMS Life Science Co., Ltd.
867.00
13.24
1.55%
JP:1375
YUKIGUNI MAITAKE CO., LTD.
1,110.00
12.45
1.13%
JP:2002
Nisshin Seifun Group Inc.
2,001.00
260.89
14.99%
JP:2936
BASE FOOD Inc.
279.00
-219.00
-43.98%
JP:3139
Lacto Japan Co., Ltd.
3,300.00
-639.98
-16.24%
JP:4526
Riken Vitamin Co., Ltd.
3,155.00
345.17
12.28%
AFC-HD AMS Life Science Co., Ltd. Corporate Events
AFC-HD AMS Life Science Posts Higher Sales but Lower Profits as Balance Sheet Strengthens
Jul 15, 2026
AFC-HD AMS Life Science Co., Ltd., listed on the Tokyo Standard market, reported third-quarter results for its fiscal year ending August 31, 2026. The general business company, active in the life science field, showed gradual asset growth and impr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.